Compare HCA Health Inc (HCA) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs Natera Inc. Common Stock — how do they compare? HCA Health Inc trades at $475 (market cap $99.75B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: HCA Health Inc is the larger of the two by market cap, and HCA Health Inc pays a 0.68% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and Natera Inc. Common Stock for 0 Days on average.
| HCA | NTRA | |
|---|---|---|
Market Cap | $99.75B | $57.03B |
Volume | 1,083,231 | 1,131,157 |
Sector | Health | Health |
52-Week High | $545.13 | $425.64 |
52-Week Low | $361.32 | $179.42 |
Typical Hold Time | 76 Days | 0 Days |
Enterprise Value | $150.29B | $56.18B |
Dividend Yield | 0.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare's stock trades at $470.44, up 2.58% today, with a bullish technical outlook and strong earnings beats in recent quarters. Revenue grew to $75.60B in 2025, with a net income margin of 8.77%, while the P/E ratio of 15.45 suggests reasonable valuation. Recent news includes an upcoming Q3 2026 earnings call and ongoing legal investigations, creating mixed sentiment.
The outlook is positive due to consistent earnings performance and analyst buy ratings, but risks include high debt levels and regulatory scrutiny. Investment opportunity lies in operational efficiency and demand growth, though investors should monitor legal developments and debt management.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
